Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 10/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GUSB | P08236 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10499384 | 0.88 | CTSD (0.49) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL3766335 | 0.84 | BACE1 (0.43) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL27578529 | 0.78 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL10926518 | 0.77 | NPC1 (0.42) | KDM4EALDH1A1HSD17B10CA12CA9 | |
| SCHEMBL171844 | 0.76 | CTSD (0.52) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL172248 | 0.76 | CYP19A1 (0.61) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL8503831 | 0.75 | MAPT (0.39) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL8669816 | 0.75 | AR (0.38) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL9059034 | 0.73 | SMN1; SMN2 (0.39) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL13351524 | 0.73 | ALDH1A1 (0.66) | KDM4EALDH1A1HPGDHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7785630-B2 | Preparation and administration form comprising an acid-labile active compound | NYCOMED GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| US-20160324723-A1 | PHARMACEUTICAL PRODUCT FOR INJECTION | TAKEDA GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| EP-1578742-B1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | NYCOMED GMBH (DE) | 2012-10-17 | — | — | EP | disclosed |
| US-20120083512-A1 | PHARMACEUTICAL PRODUCT FOR INJECTION | NYCOMED GMBH (DE) | 2012-04-05 | — | — | US | disclosed |
| EP-1658073-B1 | PHARMACEUTICAL PRODUCT FOR INJECTION | NYCOMED GMBH (DE) | 2012-02-22 | — | — | EP | disclosed |
| US-7794752-B1 | Preparation and administration form comprising an acid-labile active compound | NYCOMED GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-7790198-B2 | Preparation and administration form comprising an acid-labile active compound | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-7785630-B2 | Preparation and administration form comprising an acid-labile active compound | NYCOMED GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20090318403-A1 | ANTIBIOTIC COMPOSITION | PROSENSA TECHNOLOGIES B.V. (NL) | 2009-12-24 | — | — | US | disclosed |
| US-20090209591-A1 | Pharmaceutical product for injection | NYCOMED GMBH (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20050288334-A1 | Process for preparing optically pure active compounds | ALTANA PHARMA AG (DE) | 2005-12-29 | — | — | US | disclosed |
| WO-2005118569-A1 | PROCESS FOR THE PREPARATION OF PYRIDIN-2-YLMETHYLSULPHINYL-1H-BENZIMIDAZOL COMPOUNDS | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005107721-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING PELLETS AS WELL AS ITS MANUFACTURING PROCESS | ALTANA PHARMA AG (DE) | 2005-11-17 | — | — | WO | disclosed |
| EP-1578742-A1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | ALTANA Pharma AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1575941-A2 | PROCESS FOR PREPARING (S)-PANTOPRAZOLE | Altana Pharma AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1187601-B1 | NOVEL PREPARATION AND ADMINISTRATION FORM COMPRISING AN ACID-LABILE PROTON PUMP INHIBITOR | ALTANA PHARMA AG (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004089342-A2 | ORAL PHARMACEUTICAL PREPARATION COMPRISING A PROTON PUMP ANTAGONIST AND A BASIC EXIPIENT | ALTANA PHARMA AG (DE) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004052881-A2 | PROCESS FOR PREPARING (S)-PANTOPRAZOLE | ALTANA PHARMA AG (DE) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052882-A1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-06-24 | — | — | WO | disclosed |
| WO-1999027917-A1 | MEDICAMENT PREPARATION IN THE FORM OF A TABLET OR PELLET FOR ACID-LABILE ACTIVE SUBSTANCES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318403-A1 | ANTIBIOTIC COMPOSITION | TLR5, MYD88, CUTA | KDM4E 2272/4885ALDH1A1 3278/4885HPGD 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.